GlassScriptPhysician profile
Nina Dayen
NPI 1821248386
$4,298.56
in general payments reported to CMS, 2019-2025
33 companies · $14.57 in 2025
The $14.57 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $591 · 2021: $924 · 2022: $529 · 2023: $1,404 · 2024: $73.48 · 2025: $14.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,491.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $449.17 | 2019-2023 | Mounjaro, Jardiance |
| Pfizer INC. | $410.46 | 2019-2023 | |
| Abbvie INC. | $368.80 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Merck Sharp & Dohme LLC | $353.24 | 2019-2023 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.53 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $230.96 | 2020-2022 | |
| Allergan, INC. | $175.97 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $174.19 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $173.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $145.98 | 2022-2023 | |
| Horizon Therapeutics Plc | $138.53 | 2022-2023 | Tepezza |
| Sumitomo Pharma America, INC. | $126.35 | 2023-2024 | Aptiom |
| Pharmacosmos Therapeutics INC. | $125.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.49 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $114.37 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $101.59 | 2021 | |
| Neurelis, INC. | $93.35 | 2023 | Valtoco |
| Almatica Pharma LLC | $89.39 | 2021-2022 | |
| Vivus LLC | $86.81 | 2019-2021 | |
| Abbott Laboratories | $66.32 | 2023 | Infinity |
| Sunovion Pharmaceuticals INC. | $65.70 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.70 | 2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.23 | 2021 | |
| Jazz Pharmaceuticals INC. | $46.88 | 2023 | Xywav |
| Astellas Pharma US INC | $44.82 | 2019 | |
| Scilex Pharmaceuticals INC. | $41.02 | 2023 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $39.47 | 2023 | Rexulti, Abilify Maintena |
| Amgen INC. | $38.67 | 2019 | |
| Collegium Pharmaceutical, INC. | $24.90 | 2023 | Xtampza |
| Avanir Pharmaceuticals, INC. | $23.55 | 2022 | |
| Averitas Pharma INC. | $23.40 | 2023 | Qutenza |
| Phadia US INC. | $20.01 | 2024 | Immunocap |
| Sk Life Science, INC. | $15.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Dayen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.